ResultsIQ

ResultsIQ › Latest results › India Glycols Limited

India Glycols Limited Q1 FY27 earnings call summary

NSE: INDIAGLYCO · BSE: 500201

Earnings call of 14 Aug 2026, summarised by AI from the filing.

India Glycols Q1 FY27 net revenue ₹1,130 cr, up 9%, EBITDA ₹170 cr, up 13%; IGL Spirits FY27 EBITDA guided above ₹500 cr.

Key takeaways

  1. Q1 FY27 results Net revenue ₹1,130 cr, up 9%; EBITDA ₹170 cr, up 13%; PAT up 32%.
  2. IGL Spirits guidance FY27 EBITDA guided in excess of ₹500 cr; volume expected to double from last year.
  3. Demerger approval NCLT sanctioned the scheme on 17 July 2026; effective date to be communicated.
  4. Ennature Bio Pharma Best-ever quarter with revenue up 65% and EBITDA up 188% year-on-year.
  5. Raw material risk Raw material availability and pricing volatile and a challenge in Q2.

Original filing on BSE

India Glycols Limited Q1 FY27 results

As filed: Revenue ₹2,988 cr (+19% year on year), EBITDA ₹170 cr (+13% year on year), PAT ₹96.8 cr (+33% year on year), EBITDA margin 5.7% (−32 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹2,360 cr (+8% year on year), EBITDA ₹167 cr (+14% year on year), PAT ₹86.9 cr (+36% year on year), EBITDA margin 7.1% (+39 bps). Score 40 of 100, In line with trend. Revenue growth was below the company's own trend; EBITDA growth was well below it; profit growth was above it. EBITDA margin rose 39 bps year on year. Revenue fell 7% from last quarter. Share price after the results: −9.0% in 29 days (Nifty 500: −0.1%).
  • Q3 FY26: Revenue ₹2,551 cr (+5% year on year), EBITDA ₹175 cr (+43% year on year), PAT ₹67.6 cr (+19% year on year), EBITDA margin 6.9% (+180 bps). Score 55 of 100, In line with trend. Revenue growth was well below the company's own trend; EBITDA growth was well above it; profit growth was in line with it. EBITDA margin rose 180 bps year on year. Profit lagged EBITDA because of depreciation, interest or other income, not the business. Revenue rose ₹127 cr on a year ago, against ₹305 cr the year before. Share price after the results: −11.1% in 30 days (Nifty 500: −7.8%).
  • Q2 FY26: Revenue ₹2,412 cr (+13% year on year), EBITDA ₹157 cr (+34% year on year), PAT ₹65.0 cr (+30% year on year), EBITDA margin 6.5% (+105 bps). Score 64 of 100, In line with trend. Revenue growth was below the company's own trend; EBITDA and profit growth were above it. EBITDA margin rose 105 bps year on year. Revenue fell 4% from last quarter. Revenue rose ₹268 cr on a year ago, against ₹274 cr the year before. Share price after the results: +2.7% in 28 days (Nifty 500: −0.5%).
  • Q1 FY26: Revenue ₹2,503 cr (+10% year on year), EBITDA ₹150 cr (+19% year on year), PAT ₹73.0 cr (+22% year on year), EBITDA margin 6.0% (+47 bps). Score 48 of 100, In line with trend. Revenue and EBITDA growth were below the company's own trend; profit growth was in line with it. EBITDA margin rose 47 bps year on year. Revenue rose ₹220 cr on a year ago, against ₹389 cr the year before.
  • Q4 FY25: Revenue ₹2,189 cr (+7% year on year), EBITDA ₹146 cr (+39% year on year), PAT ₹64.0 cr (+52% year on year), EBITDA margin 6.7% (+152 bps). Score 60 of 100, In line with trend. Revenue growth was well below the company's own trend; EBITDA and profit growth were well above it. EBITDA margin rose 152 bps year on year. Revenue fell 10% from last quarter. Revenue rose ₹150 cr on a year ago, against ₹423 cr the year before. Share price after the results: +7.6% in 28 days (Nifty 500: +0.2%).
  • Q3 FY25: Revenue ₹2,424 cr (+14% year on year), EBITDA ₹123 cr (+22% year on year), PAT ₹57.0 cr (+36% year on year), EBITDA margin 5.1% (+31 bps). Score 49 of 100, In line with trend. Revenue growth was well below the company's own trend; EBITDA growth was in line with it; profit growth was well above it. EBITDA margin rose 31 bps year on year. Revenue rose ₹305 cr on a year ago, against ₹595 cr the year before.
  • Q2 FY25: Revenue ₹2,144 cr (+15% year on year), EBITDA ₹117 cr (+23% year on year), PAT ₹50.0 cr (+32% year on year), EBITDA margin 5.5% (+38 bps). Score 65 of 100, In line with trend. EBITDA margin rose 38 bps year on year. Not enough history for a trend yet: scored on growth alone. Revenue fell 6% from last quarter.

Past price moves after results do not indicate future moves. Not a recommendation.

India Glycols Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.